Exelixis Inc (EXEL) reports robust financial results driven by the cabozantinib franchise, while navigating competitive and ...

Exelixis (EXEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).